Imbruvica ibrutinib: Clinical trial data

Data from 5 patients with high-risk, relapsed/refractory CLL who underwent prior allogeneic HSCT showed that salvage therapy with Imbruvica reduced lymph node size in 4 patients by an average of 68% after 3 months. Imbruvica led to undetectable minimal residual disease in 2 patients. Additionally, 1 of those patients achieved engraftment of donor cells after 1 year of Imbruvica treatment and maintained undetectable minimal residual disease for >=10 months after stopping treatment. Data were presented at the American Society for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research meeting in San Diego. ...